EvoNext Holdings Overview
- Year Founded
-
2004
- Status
-
Acquired/Merged
- Employees
-
72
- Latest Deal Type
-
2ndary - Private
EvoNext Holdings General Information
Description
EvoNext Holdings SA has no operating business.
Contact Information
Website
www.evonextholdings.com(Operating Subsidiary)
Corporate Office
- Duggingerstrasse 23
- 4153 Reinach
- Switzerland
Corporate Office
- Duggingerstrasse 23
- 4153 Reinach
- Switzerland
EvoNext Holdings Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Secondary Transaction - Private | 30-Dec-2024 | Completed | Generating Revenue | |||
| 11. Merger/Acquisition | 28-Dec-2023 | Completed | Generating Revenue | |||
| 10. PIPE | 24-May-2022 | Completed | Generating Revenue | |||
| 9. PIPE | 30-Nov-2021 | Completed | Generating Revenue | |||
| 8. Secondary Transaction - Private | 01-Jun-2018 | Completed | Generating Revenue | |||
| 7. PIPE | 08-Nov-2017 | Completed | Generating Revenue | |||
| 6. PIPE | 27-Mar-2013 | Completed | Generating Revenue | |||
| 5. Reverse Merger | 11-Dec-2009 | Completed | Generating Revenue | |||
| 4. Accelerator/Incubator | $53.2M | Completed | Startup | |||
| 3. Debt - General | 01-Dec-2009 | $43.7M | $53.2M | Completed | Startup |
EvoNext Holdings Comparisons
Industry
Financing
Details
EvoNext Holdings Competitors (1)
One of EvoNext Holdings’s competitors is Amyris (Biotechnology), a Private Equity-Backed company based in Emeryville, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Amyris (Biotechnology) | Private Equity-Backed | Emeryville, CA |
EvoNext Holdings Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
EvoNext Holdings Patents
EvoNext Holdings Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-2970934-A1 | Valencene synthase polypeptides, encoding nucleic acid molecules and uses thereof | Active | 14-Mar-2013 | ||
| EP-2970934-B1 | Valencene synthase polypeptides, encoding nucleic acid molecules and uses thereof | Active | 14-Mar-2013 | ||
| EP-3085778-A1 | Valencene synthase polypeptides, encoding nucleic acid molecules and uses thereof | Active | 14-Mar-2013 | ||
| EP-3085778-B1 | Valencene synthase polypeptides, encoding nucleic acid molecules and uses thereof | Active | 14-Mar-2013 | ||
| ES-2891377-T3 | Valencene synthase polypeptides, encoding nucleic acid molecules, and uses thereof | Active | 14-Mar-2013 | C12N9/88 |
EvoNext Holdings Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
EvoNext Holdings Former Investors (26)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Aravis | Growth/Expansion | Minority | ||
| Arpida | Corporation | Minority | ||
| Astellas Venture Management | Corporate Venture Capital | Minority | ||
| Auriga Partners (Paris) | Venture Capital | Minority | ||
| BioMedPartners | Venture Capital | Minority |
EvoNext Holdings Acquisitions (8)
EvoNext Holdings’s most recent deal was a Reverse Merger with AIM Sport. The deal was made on 12-Oct-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| AIM Sport | 12-Oct-2026 | Reverse Merger | Media and Information Services (B2B) | ||
| Allylix | 16-Dec-2014 | Merger/Acquisition | Specialty Chemicals | ||
| Prosarix | 31-Jul-2014 | Merger/Acquisition | Other Pharmaceuticals and Biotechnology | ||
| Fluxome Sciences | 29-Nov-2012 | Merger/Acquisition | Other Pharmaceuticals and Biotechnology | ||
| Fluxome Sciences (Resveratrol Business) | 29-Nov-2012 | Merger/Acquisition | Food Products |
EvoNext Holdings ESG
Risk Overview
Risk Rating
Updated October, 31, 2023
46.48 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,766
Rank
Percentile
Chemicals
Industry
of 579
Rank
Percentile
Specialty Chemicals
Subindustry
of 148
Rank
Percentile
EvoNext Holdings FAQs
-
When was EvoNext Holdings founded?
EvoNext Holdings was founded in 2004.
-
Where is EvoNext Holdings headquartered?
EvoNext Holdings is headquartered in Reinach, Switzerland.
-
What is the size of EvoNext Holdings?
EvoNext Holdings has 72 total employees.
-
What industry is EvoNext Holdings in?
EvoNext Holdings’s primary industry is Biotechnology.
-
Is EvoNext Holdings a private or public company?
EvoNext Holdings is a Private company.
-
What is EvoNext Holdings’s current revenue?
The current revenue for EvoNext Holdings is .
-
How much funding has EvoNext Holdings raised over time?
EvoNext Holdings has raised $122M.
-
Who are EvoNext Holdings’s investors?
Aravis, Arpida, Astellas Venture Management, Auriga Partners (Paris), and BioMedPartners are 5 of 26 investors who have invested in EvoNext Holdings.
-
Who are EvoNext Holdings’s competitors?
Amyris (Biotechnology) is a competitor of EvoNext Holdings.
-
When was EvoNext Holdings acquired?
EvoNext Holdings was acquired on 30-Dec-2024.
-
Who acquired EvoNext Holdings?
EvoNext Holdings was acquired by Danstar Ferment.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
